Level Trailhead 61

Chemical identity / technical primer

Molecular Profile

Ibogaine is a structurally elaborate monoterpenoid indole alkaloid: one molecule with a fused, bridged iboga scaffold, an indole system, a tertiary amine, and a methoxy substituent.

This page focuses on chemical identity rather than treatment claims. For the wider evidence-first context around ibogaine as a research subject, the site’s main overview sets out the same safety-conscious frame.

Laboratory view accompanying an evidence-based look at ibogaine molecular structure

A compound’s structure is not a shorthand for its safety, effects, or suitability.

Names, formulas, and registry entries identify a compound; they do not settle its biological behavior in people.

01 / Identity markers

One formula, several useful ways to name it

Ibogaine’s molecular formula is C20H26N2O, with a molecular weight of approximately 310.44 g/mol. Its commonly used name is ibogaine; systematic records commonly give the IUPAC name (1R,9S,13S,14R)-12-methoxy-13-methyl-2,3,4,6,7,8,9,13,14,15-decahydro-1H-1,9-methanopyrido[1′,2′:1,2]azepino[5,4-b]indole.

Identifier databases are useful for checking that nomenclature, formula, and structure resolve to the same compound. The PubChem compound record for ibogaine, the ChemSpider structure entry, and CAS registry material each serve different indexing and reference functions. A database match is a starting point for chemical identification, not an account of pharmacology or risk.

Ibogaine is often discussed alongside clinical settings, but an account of molecular structure should remain separate from decisions about care. Pages concerning ibogaine treatment in Arizona involve setting-specific claims that cannot be inferred from a skeletal formula alone.

02 / Reading the scaffold

A compact drawing hides a crowded three-dimensional framework

Ibogaine’s 2D structure maps connectivity. Its 3D structure determines the spatial arrangement of that connectivity.

In a two-dimensional chemical drawing, the indole ring is the familiar aromatic region: a benzene ring fused to a five-membered nitrogen-containing ring. The remaining framework folds into the characteristic iboga skeleton, a rigid, bridged polycyclic system containing a tertiary amine.

Three-dimensional models make the constraint more apparent. Several saturated rings, bridge positions, and stereocenters hold substituents in specific orientations. That architecture is why an image of the molecule is more than a collection of atom labels: spatial arrangement changes how a compound can fit, ionize, and be transformed.

Structural features

Indole, amine, ether

The indole nitrogen is part of an aromatic system and can act as a hydrogen-bond donor. The tertiary amine is the more readily protonated basic site. The methoxy group is an aryl ether attached to the aromatic portion of the framework.

Those motifs support a molecule with substantial nonpolar surface and a limited set of heteroatoms. That balance is relevant to lipophilicity, hydrogen-bonding patterns, and acid–base behavior, while still falling short of a full prediction of behavior in a biological system.

Close laboratory composition illustrating the spatial complexity of ibogaine's polycyclic structure

03 / Stereochemistry

Chirality is part of the identity

Ibogaine has multiple chiral centers. Structure records for the naturally associated configuration commonly designate them as 1R, 9S, 13S, and 14R. These absolute descriptors specify the arrangement around each stereogenic center under the Cahn–Ingold–Prelog convention.

The distinction matters because stereoisomers can share a formula and even a 2D connectivity pattern while differing in three-dimensional shape. The IUPAC definition of stereoisomerism helps clarify why a name that omits configuration is less chemically specific than a fully stereodescribed record.

In ibogaine, the bridge-rich scaffold limits conformational freedom compared with a simple flexible chain. It does not make the molecule static, but it does make stereochemistry central to a faithful structural description.

04 / Properties and metabolism

How motifs guide cautious physicochemical expectations

The tertiary amine gives ibogaine a basic site, so the proportion present in protonated form changes with pH. The hydrophobic fused-ring framework and aromatic surface contribute to lipophilicity, while the indole nitrogen and methoxy oxygen provide a limited hydrogen-bonding pattern. These are structural cues, not a substitute for measured values under stated conditions.

The aryl methoxy substituent is also chemically relevant to metabolism. CYP2D6-mediated O-demethylation can convert ibogaine to noribogaine, making the methoxy-bearing aromatic site a recognized oxidative vulnerability. The NCBI pharmacogenetics overview of CYP2D6 provides context for why enzyme variation can matter when interpreting CYP2D6-linked metabolism.

Metabolic descriptions should not be converted into treatment claims. Discussions of ibogaine aftereffects require clinical and safety context beyond a molecule’s functional groups, and chemical structure alone cannot establish individual outcomes.

05 / Clarifying terms

A short structure-focused FAQ

These answers stay with chemical identity and the limits of structural interpretation.

What is ibogaine’s molecular formula?

Ibogaine has the molecular formula C20H26N2O and an average molecular weight of about 310.44 g/mol. This identifies elemental composition, not stereochemical configuration or biological action.

Is ibogaine one molecule or a mixture?

Ibogaine refers to a defined compound. Its stereochemical form is part of that definition because the structure contains several chiral centers. Related alkaloids, metabolites, and preparations are separate chemical questions.

Why does CYP2D6 matter to the molecule?

CYP2D6 is associated with O-demethylation of ibogaine to noribogaine, tying metabolism to the molecule’s aromatic methoxy group. That reaction pathway does not by itself predict exposure or outcomes for an individual.

Can chemical structure establish where or whether ibogaine should be used?

No. A structural profile cannot establish the safety, quality, oversight, or appropriateness of a provider or setting. Questions about ibogaine clinics in Costa Rica, ibogaine for alcohol addiction, or treatment centers in Canada require evidence and safety evaluation that lie outside molecular nomenclature.

Continue with context

Keep the molecule and the claims separate.

For connected questions about structural motifs and biological interpretation, use the site’s structure–pharmacology map. For scope, methods, and independence, see how this resource frames its work.

Claims about ibogaine clinics in Mexico should likewise be assessed on their own evidence rather than projected from ibogaine’s molecular profile.

Chemistry & analysis